

**CORDLIFE GROUP LIMITED**  
(Company Registration No.: 200102883E)  
(Incorporated in the Republic of Singapore)

---

**PROFIT WARNING ON THE UNAUDITED FINANCIAL RESULTS FOR THE FINANCIAL YEAR  
ENDED 31 DECEMBER 2023**

---

The Board of Directors of Cordlife Group Limited (the "**Company**") and together with its subsidiaries, the "**Group**") wishes to announce that, based on a preliminary assessment of the Group's draft unaudited financial results for the financial year ended 31 December 2023 ("**FY2023**", and "**Unaudited FY2023 Results**" respectively), the Group expects to report a material decline in profit for FY2023.

As stated in the Company's announcements on 30 November 2023, 13 December 2023, 15 December 2023 and 23 January 2024, the Company had, among others, accepted the notice from the Ministry of Health ("**MOH**") to stop for a period of up to six months, the collection, testing, processing and/or storage of any new cord blood and human tissues, or the provision of any new types of tests to patients in Singapore, and is working with the MOH to rectify any potential areas of non-compliance with the Healthcare Services (General) Regulations and the Healthcare Services (Cord Blood Banking Services) Regulations that the MOH has identified in relation to the Company's operations in Singapore. In connection with the foregoing, the Company anticipates that its net profit for FY2023 will decline by approximately 25%-30% as compared to the financial year ended 31 December 2022. Further, as stated in the Company's announcement on 17 January 2024, since the end of December 2023, the Company has also started sending donated cord blood samples from the affected tanks under investigation to a third-party laboratory in Singapore licensed by MOH for viability testing in batches. Due to the uncertainty of the outcome of the ongoing testing which is estimated to be ready only in end-March 2024, the Company is at present unable to assess the impact of the investigations on the Unaudited FY2023 Results. However, if the results of the testing confirm that any of the affected tanks are adversely affected by the temperature excursions, such results may have a further adverse impact on the Unaudited FY2023 Results.

This profit warning is based on a preliminary review of the Group's draft Unaudited FY2023 Results. Further details will be disclosed when the Group announces its Unaudited FY2023 Results, which will be released on or before 29 February 2024.

In the meantime, shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company. They should consult their stockbrokers, bank managers, solicitors, or other professional advisers if they have any doubt about the actions they should take.

For and on behalf of the Board  
**CORDLIFE GROUP LIMITED**

Low Mei Wan  
Company Secretary

27 February 2024